- Home
- / Denali Therapeutics
Denali Therapeutics
Stock Price
$27.5
2024-10-29
Market Capitalization
$4 B
2024-10-28
Revenue
$330.5 M
FY, 2023
Denali Therapeutics Summary
Company Summary
- Overview
- Denali Therapeutics is a clinical stage biopharmaceutical company. It develops products that are able to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage diseases (LSDs).
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- South San Francisco, CA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Ryan Watts, Chief Executive Officer, Director
Carole Ho, Chief Medical Officer
Steve Krognes, Chief Financial Officer
LocationsView all
3 locations detected
South San Francisco, CA HQ
United States
161 Oyster Point Blvd
Zürich, ZH
Switzerland
Schützengasse 1
London, England
United Kingdom
2 New St Square
Denali Therapeutics Financials
Summary Financials
- Net income (Q3, 2024)
- ($107.2M)
- Cash (Q3, 2024)
- $90.6M
- EBIT (Q3, 2024)
- ($123.2M)
- Enterprise value
- $3.9B